ACS Medicinal Chemistry Letters
Letter
physicochemical and pharmacokinetic properties, efficacies, and
activities. ChemMedChem 2015, 10, 461−469.
(29) Magnaghi, P.; D’alessio, R.; Valsasina, B.; Avanzi, N.; Rizzi, S.;
Asa, D.; Gasparri, F.; Cozzi, L.; Cucchi, U.; Orrenius, C.; Polucci, P.;
Ballinari, D.; Perrera, C.; Leone, A.; Cervi, G.; Casale, E.; Xiao, Y.;
Wong, C.; Anderson, D. J.; Galvani, A.; Donati, D.; O’Brien, T.;
Jackson, P. K.; Isacchi, A. Covalent and allosteric inhibitors of the
ATPase VCP/p97 induce cancer cell death. Nat. Chem. Biol. 2013, 9,
548−556.
(30) Polucci, P.; Magnaghi, P.; Angiolini, M.; Asa, D.; Avanzi, N.;
Badari, A.; Bertrand, J.; Casale, E.; Cauteruccio, S.; Cirla, A.; Cozzi, L.;
Galvani, A.; Jackson, P. K.; Liu, Y.; Magnuson, S.; Malgesini, B.;
Nuvoloni, S.; Orrenius, C.; Sirtori, F. R.; Riceputi, L.; Rizzi, S.;
Trucchi, B.; O’Brien, T.; Isacchi, A.; Donati, D.; D’alessio, R.
Alkylsulfanyl-1,2,4-triazoles, a new class of allosteric valosine
containing protein inhibitors. Synthesis and structure-activity relation-
ships. J. Med. Chem. 2013, 56, 437−450.
(31) Kakizuka, A.; Hori, S.; Shudo, T.; Fuchigami, T. Preparation of
2-(arylazo or heteroarylazo)-4-aminonaphthalene-1-sulfonic acid de-
rivatives as regulators of vasolin-containing protein (VCP). PCT Int.
Appl. WO 2012014994, 2012.
(32) Wang, Q.; Li, L.; Ye, Y. Inhibition of p97-dependent protein
degradation by eeyarestatin I. J. Biol. Chem. 2008, 283, 7445−7454.
(33) Yi, P.; Higa, A.; Taouji, S.; Bexiga, M. G.; Marza, E.; Arma, D.;
Castain, C.; Le Bail, B.; Simpson, J. C.; Rosenbaum, J.; Balabaud, C.;
Bioulac-Sage, P.; Blanc, J.-F.; Chevet, E. Sorafenib-mediated targeting
of the AAA+ ATPase p97/VCP leads to disruption of the secretory
pathway, endoplasmic reticulum stress, and hepatocellular cancer cell
death. Mol. Cancer Ther. 2012, 11, 2610−2620.
(11) Micheli, F.; Andreotti, D.; Braggio, S.; Checchia, A. A specific
and direct comparison of the trifluoromethyl and pentafluorosulfanyl
groups on the selective dopamine D3 antagonist 3-(3-{[4-methyl-5-(4-
methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-1-phenyl-3-
azabicyclo[3.1.0]hexane template. Bioorg. Med. Chem. Lett. 2010, 20,
4566−4568.
(12) Karagiannidis, L. E.; Haynes, C. J. E.; Holder, K. J.; Kirby, I. L.;
Moore, S. J.; Wells, N. J.; Gale, P. A. Highly effective yet simple
transmembrane anion transporters based upon ortho-phenylenedi-
amine bis-ureas. Chem. Commun. 2014, 50, 12050−12053.
(13) Barnes-Seeman, D.; Beck, J.; Springer, C. Fluorinated
compounds in medicinal chemistry: recent applications, synthetic
advances and matched-pair analyses. Curr. Top. Med. Chem. 2014, 14,
855−864.
(14) Altomonte, S.; Baillie, G. L.; Ross, R. A.; Riley, J.; Zanda, M. The
pentafluorosulfanyl group in cannabinoid receptor ligands: synthesis
and comparison with trifluoromethyl and tert-butyl analogues. RSC
Adv. 2014, 4, 20164−20176.
(15) Chia, P. W.; Brennan, S. C.; Slawin, A. M. Z.; Riccardi, D.;
O’Hagan, D. Allosteric agonists of the calcium receptor (CaR):
Fluorine and SF5 analogues of cinacalcet. Org. Biomol. Chem. 2012, 10,
7922−7927.
(16) Mo, T.; Mi, X.; Milner, E. E.; Dow, G. S.; Wipf, P. Synthesis of
an 8-pentafluorosulfanyl analog of the antimalarial agent mefloquine.
Tetrahedron Lett. 2010, 51, 5137−5140.
(17) Woodman, P. G. p97, a protein coping with multiple identities.
J. Cell Sci. 2003, 116, 4283−4290.
(18) Li, G.; Huang, C.; Zhao, G.; Lennarz, W. J. Interprotomer
motion-transmission mechanism for the hexameric AAA ATPase p97.
Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 3737−3741.
(19) Davies, J. M.; Brunger, A. T.; Weis, W. I. Improved structures of
full-length p97, an AAA ATPase: Implications for mechanisms of
nucleotide-dependent conformational change. Structure 2008, 16,
715−726.
(20) Brandvold, K. R.; Morimoto, R. I. The chemical biology of
molecular chaperones-implications for modulation of proteostasis. J.
Mol. Biol. 2015, 427, 2931−2947.
(21) Manos-Turvey, A.; Brodsky, J.; Wipf, P. The effect of structure
and mechanism of the Hsp70 chaperone on the ability to identify
chemical modulators and therapeutics. Top. Med. Chem. 2015, 16, 1−
49.
(22) Deshaies, R. J. Proteotoxic crisis, the ubiquitin-proteasome
system, and cancer therapy. BMC Biol. 2014, 12, 94.
(23) Haines, D. S. p97-containing complexes in proliferation control
and cancer: emerging culprits or guilt by association? Genes Cancer
2010, 1, 753−763.
(24) Chapman, E.; Maksim, N.; De La Cruz, F.; La Clair, J. J.
Inhibitors of the AAA+ chaperone p97. Molecules 2015, 20, 3027−
3049.
(34) Tao, S.; Tillotson, J.; Wijeratne, E. M. K.; Xu, Y.-M.; Kang, M.;
Wu, T.; Lau, E. C.; Mesa, C.; Mason, D. J.; Brown, R. V.; La Clair, J. J.;
Gunatilaka, A. A. L.; Zhang, D. D.; Chapman, E. Withaferin A analogs
that target the AAA+ chaperone p97. ACS Chem. Biol. 2015, 10,
1916−1924.
(35) Kang, M. J.; Wu, T.; Wijeratne, E. M. K.; Lau, E. C.; Mason, D.
J.; Mesa, C.; Tillotson, J.; Zhang, D. D.; Gunatilaka, A. a. L.; La Clair, J.
J.; Chapman, E. Functional chromatography reveals three natural
products that target the same protein with distinct mechanisms of
action. ChemBioChem 2014, 15, 2125−2131.
(36) Manuscript in preparation.
(37) Chou, T.-F.; Bulfer, S. L.; Weihl, C. C.; Li, K.; Lis, L. G.;
Walters, M. A.; Schoenen, F. J.; Lin, H. J.; Deshaies, R. J.; Arkin, M. R.
Specific inhibition of p97/VCP ATPase and kinetic analysis
demonstrate interaction between D1 and D2 ATPase domains. J.
Mol. Biol. 2014, 426, 2886−2899.
(38) Wei, Y.; Deb, I.; Yoshikai, N. Palladium-catalyzed aerobic
oxidative cyclization of N-aryl imines: indole synthesis from anilines
and ketones. J. Am. Chem. Soc. 2012, 134, 9098−9101.
(39) Harris, M. C.; Huang, X.; Buchwald, S. L. Improved functional
group compatibility in the palladium-catalyzed synthesis of aryl
amines. Org. Lett. 2002, 4, 2885−2888.
(40) Kazock, J.-Y.; Thery, I.; Chezal, J.-M.; Chavignon, O.; Teulade,
J.-C.; Gueiffier, A.; Enguehard-Gueiffier, C. From the particular
reactivity of 8-iodoimidazo[1,2-a]pyridine towards copper- and
palladium-catalyzed aminations. Bull. Chem. Soc. Jpn. 2006, 79, 775−
779.
(25) Chou, T.-F.; Brown, S. J.; Minond, D.; Nordin, B. E.; Li, K.;
Jones, A. C.; Chase, P.; Porubsky, P. R.; Stoltz, B. M.; Schoenen, F. J.;
Patricelli, M. P.; Hodder, P.; Rosen, H.; Deshaies, R. J. Reversible
inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and
autophagic protein clearance pathways. Proc. Natl. Acad. Sci. U. S. A.
2011, 108, 4834−4839.
(26) Fang, C.-J.; Gui, L.; Zhang, X.; Moen, D. R.; Li, K.; Frankowski,
K. J.; Lin, H. J.; Schoenen, F. J.; Chou, T.-F. Evaluating p97 inhibitor
analogues for their domain selectivity and potency against the p97-p47
complex. ChemMedChem 2015, 10, 52−56.
(27) Zhou, H.-J.; Parlati, F.; Wustrow, D. Preparation of fused
pyrimidines as inhibitors of p97 complex. Patent WO2014015291,
2014.
(42) Joucla, L.; Batail, N.; Djakovitch, L. ″On water″ direct and site-
selective Pd-catalysed C-H arylation of (NH)-indoles. Adv. Synth.
Catal. 2010, 352, 2929−2936.
̌
(43) Iakobson, G.; Posta, M.; Beier, P. Synthesis of pentafluor-
osulfanyl-containing indoles and oxindoles. Synlett 2013, 24, 855−859.
(44) Kuehne, M. E.; Kitagawa, T. Reactions of indoles with benzyne.
J. Org. Chem. 1964, 29, 1270−1273.
(45) Noland, W. E.; Rush, K. R.; Smith, L. R. Nitration of indoles. IV.
Nitration of 2-phenylindole. J. Org. Chem. 1966, 31, 65−69.
(46) Electron-density surfaces encoded with electrostatic potential
maps were calculated in Spartan 10 (Wave Function, Inc., Irvine, CA)
with PM3 parametrization.
(28) Bursavich, M. G.; Parker, D. P.; Willardsen, J. A.; Gao, Z.-H.;
Davis, T.; Ostanin, K.; Robinson, R.; Peterson, A.; Cimbora, D. M.;
Zhu, J.-F.; Richards, B. 2-Anilino-4-aryl-1,3-thiazole inhibitors of
valosin-containing protein (VCP or p97). Bioorg. Med. Chem. Lett.
2010, 20, 1677−1679.
(47) Hendriks, C. M. M.; Penning, T. M.; Zang, T.; Wiemuth, D.;
Grunder, S.; Sanhueza, I. A.; Schoenebeck, F.; Bolm, C. Penta-
̈
E
ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX